Minocycline Is Not Effective in Systemic Sclerosis: Results of an Open-Label Multicenter Trial

Maureen D. Mayes, Daniel O'Donnell, Naomi F. Rothfield, M. E. Csuka

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objective. To determine if minocycline therapy improved skin thickness in early, diffuse systemic sclerosis (SSc) by ≥30%, a level of improvement unlikely to occur in the natural history of the disease as determined by recent controlled trials. Methods. Subjects with diffuse SSc of ≤5 years' duration were treated with oral minocycline for 1 year. The primary outcome measure was the modified Rodnan skin thickness score (MRSS). Results. Of 36 subjects initially enrolled, 31 returned for at least 1 followup visit and were included in the analysis (modified intent-to-treat analysis). The group consisted of 23 women and 8 men, with a mean age of 51.7 years (range 26-82 years) and a mean disease duration of 23.5 months (range 6-60 months). The mean MRSS at entry was 22.7 (range 12-43), and at the final visit it was 18.6 (range 2-48). There was no statistically significant difference in the change in skin scores between the minocycline-treated subjects and subjects previously reported in the D-penicillamine (D-Pen) trial. In addition, when adjusted for disease duration, a comparison of MRSS in the minocycline trial subjects (including all subjects active at each time point) and the previously reported D-Pen trial subjects showed no difference and no treatment effect. Fourteen subjects did not complete all 12 months of treatment; 10 of them withdrew due to disease progression. Disease duration was significantly shorter for the noncompleters than for the completers (P <0.03). Conclusion. The degree of change in the MRSS was similar to that expected in the natural course of this disease. Based on these data, minocycline is not an effective therapy for SSc.

Original languageEnglish (US)
Pages (from-to)553-557
Number of pages5
JournalArthritis and Rheumatism
Volume50
Issue number2
DOIs
StatePublished - Feb 2004
Externally publishedYes

Fingerprint

Minocycline
Systemic Scleroderma
Multicenter Studies
Skin
Diffuse Scleroderma
Penicillamine
Therapeutics
Disease Progression
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Minocycline Is Not Effective in Systemic Sclerosis : Results of an Open-Label Multicenter Trial. / Mayes, Maureen D.; O'Donnell, Daniel; Rothfield, Naomi F.; Csuka, M. E.

In: Arthritis and Rheumatism, Vol. 50, No. 2, 02.2004, p. 553-557.

Research output: Contribution to journalArticle

Mayes, Maureen D. ; O'Donnell, Daniel ; Rothfield, Naomi F. ; Csuka, M. E. / Minocycline Is Not Effective in Systemic Sclerosis : Results of an Open-Label Multicenter Trial. In: Arthritis and Rheumatism. 2004 ; Vol. 50, No. 2. pp. 553-557.
@article{b576cb390685411e91489473eccbb759,
title = "Minocycline Is Not Effective in Systemic Sclerosis: Results of an Open-Label Multicenter Trial",
abstract = "Objective. To determine if minocycline therapy improved skin thickness in early, diffuse systemic sclerosis (SSc) by ≥30{\%}, a level of improvement unlikely to occur in the natural history of the disease as determined by recent controlled trials. Methods. Subjects with diffuse SSc of ≤5 years' duration were treated with oral minocycline for 1 year. The primary outcome measure was the modified Rodnan skin thickness score (MRSS). Results. Of 36 subjects initially enrolled, 31 returned for at least 1 followup visit and were included in the analysis (modified intent-to-treat analysis). The group consisted of 23 women and 8 men, with a mean age of 51.7 years (range 26-82 years) and a mean disease duration of 23.5 months (range 6-60 months). The mean MRSS at entry was 22.7 (range 12-43), and at the final visit it was 18.6 (range 2-48). There was no statistically significant difference in the change in skin scores between the minocycline-treated subjects and subjects previously reported in the D-penicillamine (D-Pen) trial. In addition, when adjusted for disease duration, a comparison of MRSS in the minocycline trial subjects (including all subjects active at each time point) and the previously reported D-Pen trial subjects showed no difference and no treatment effect. Fourteen subjects did not complete all 12 months of treatment; 10 of them withdrew due to disease progression. Disease duration was significantly shorter for the noncompleters than for the completers (P <0.03). Conclusion. The degree of change in the MRSS was similar to that expected in the natural course of this disease. Based on these data, minocycline is not an effective therapy for SSc.",
author = "Mayes, {Maureen D.} and Daniel O'Donnell and Rothfield, {Naomi F.} and Csuka, {M. E.}",
year = "2004",
month = "2",
doi = "10.1002/art.20036",
language = "English (US)",
volume = "50",
pages = "553--557",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Minocycline Is Not Effective in Systemic Sclerosis

T2 - Results of an Open-Label Multicenter Trial

AU - Mayes, Maureen D.

AU - O'Donnell, Daniel

AU - Rothfield, Naomi F.

AU - Csuka, M. E.

PY - 2004/2

Y1 - 2004/2

N2 - Objective. To determine if minocycline therapy improved skin thickness in early, diffuse systemic sclerosis (SSc) by ≥30%, a level of improvement unlikely to occur in the natural history of the disease as determined by recent controlled trials. Methods. Subjects with diffuse SSc of ≤5 years' duration were treated with oral minocycline for 1 year. The primary outcome measure was the modified Rodnan skin thickness score (MRSS). Results. Of 36 subjects initially enrolled, 31 returned for at least 1 followup visit and were included in the analysis (modified intent-to-treat analysis). The group consisted of 23 women and 8 men, with a mean age of 51.7 years (range 26-82 years) and a mean disease duration of 23.5 months (range 6-60 months). The mean MRSS at entry was 22.7 (range 12-43), and at the final visit it was 18.6 (range 2-48). There was no statistically significant difference in the change in skin scores between the minocycline-treated subjects and subjects previously reported in the D-penicillamine (D-Pen) trial. In addition, when adjusted for disease duration, a comparison of MRSS in the minocycline trial subjects (including all subjects active at each time point) and the previously reported D-Pen trial subjects showed no difference and no treatment effect. Fourteen subjects did not complete all 12 months of treatment; 10 of them withdrew due to disease progression. Disease duration was significantly shorter for the noncompleters than for the completers (P <0.03). Conclusion. The degree of change in the MRSS was similar to that expected in the natural course of this disease. Based on these data, minocycline is not an effective therapy for SSc.

AB - Objective. To determine if minocycline therapy improved skin thickness in early, diffuse systemic sclerosis (SSc) by ≥30%, a level of improvement unlikely to occur in the natural history of the disease as determined by recent controlled trials. Methods. Subjects with diffuse SSc of ≤5 years' duration were treated with oral minocycline for 1 year. The primary outcome measure was the modified Rodnan skin thickness score (MRSS). Results. Of 36 subjects initially enrolled, 31 returned for at least 1 followup visit and were included in the analysis (modified intent-to-treat analysis). The group consisted of 23 women and 8 men, with a mean age of 51.7 years (range 26-82 years) and a mean disease duration of 23.5 months (range 6-60 months). The mean MRSS at entry was 22.7 (range 12-43), and at the final visit it was 18.6 (range 2-48). There was no statistically significant difference in the change in skin scores between the minocycline-treated subjects and subjects previously reported in the D-penicillamine (D-Pen) trial. In addition, when adjusted for disease duration, a comparison of MRSS in the minocycline trial subjects (including all subjects active at each time point) and the previously reported D-Pen trial subjects showed no difference and no treatment effect. Fourteen subjects did not complete all 12 months of treatment; 10 of them withdrew due to disease progression. Disease duration was significantly shorter for the noncompleters than for the completers (P <0.03). Conclusion. The degree of change in the MRSS was similar to that expected in the natural course of this disease. Based on these data, minocycline is not an effective therapy for SSc.

UR - http://www.scopus.com/inward/record.url?scp=1042290310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1042290310&partnerID=8YFLogxK

U2 - 10.1002/art.20036

DO - 10.1002/art.20036

M3 - Article

C2 - 14872498

AN - SCOPUS:1042290310

VL - 50

SP - 553

EP - 557

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 2

ER -